379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| id |
doaj-09ff01cfe15f46dcb1d7e5a4c78e65f3 |
|---|---|
| record_format |
Article |
| spelling |
doaj-09ff01cfe15f46dcb1d7e5a4c78e65f32020-12-11T10:01:45ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0379379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptorGareth Betts0Natalie Bath1Mark Dudley2Tanner Johanns3Ahmed Galal4Samuel Saibil5Adrian Sacher6Spinner William7Alex Tipping8Jessica Tucci9Raymond Luke10Trupti Trivedi11Quan Lin12Karen Miller13Aff80 Adaptimmune Philadelphia PA USA Aff80 Adaptimmune Philadelphia PA USA Aff1 grid.410305.30000 0001 2194 5650National Cancer InstituteSurgery Branch Bethesda MD USA 3Washington University School of Medicine, St. Louis, USA2Duke Cancer Center, Durham, NC, USA4Princess Margaret Cancer Centre, Toronto, Canada4Princess Margaret Cancer Centre, Toronto, Canada5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA5Adaptimmune, Philadelphia, PA, USA |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Gareth Betts Natalie Bath Mark Dudley Tanner Johanns Ahmed Galal Samuel Saibil Adrian Sacher Spinner William Alex Tipping Jessica Tucci Raymond Luke Trupti Trivedi Quan Lin Karen Miller |
| spellingShingle |
Gareth Betts Natalie Bath Mark Dudley Tanner Johanns Ahmed Galal Samuel Saibil Adrian Sacher Spinner William Alex Tipping Jessica Tucci Raymond Luke Trupti Trivedi Quan Lin Karen Miller 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor Journal for ImmunoTherapy of Cancer |
| author_facet |
Gareth Betts Natalie Bath Mark Dudley Tanner Johanns Ahmed Galal Samuel Saibil Adrian Sacher Spinner William Alex Tipping Jessica Tucci Raymond Luke Trupti Trivedi Quan Lin Karen Miller |
| author_sort |
Gareth Betts |
| title |
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor |
| title_short |
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor |
| title_full |
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor |
| title_fullStr |
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor |
| title_full_unstemmed |
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor |
| title_sort |
379 initial safety, efficacy, and product attributes from the surpass trial with adp-a2m4cd8, a spear t-cell therapy incorporating an affinity optimized tcr targeting mage-a4 and a cd8α co-receptor |
| publisher |
BMJ Publishing Group |
| series |
Journal for ImmunoTherapy of Cancer |
| issn |
2051-1426 |
| publishDate |
2020-11-01 |
| work_keys_str_mv |
AT garethbetts 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT nataliebath 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT markdudley 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT tannerjohanns 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT ahmedgalal 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT samuelsaibil 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT adriansacher 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT spinnerwilliam 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT alextipping 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT jessicatucci 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT raymondluke 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT truptitrivedi 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT quanlin 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor AT karenmiller 379initialsafetyefficacyandproductattributesfromthesurpasstrialwithadpa2m4cd8aspeartcelltherapyincorporatinganaffinityoptimizedtcrtargetingmagea4andacd8acoreceptor |
| _version_ |
1724386525685219328 |